TY  - JOUR
  - Moore AC, Hill AV
  - 2004
  - June
  - Immunological Reviews
  - Progress in DNA-based heterologous prime-boost immunization strategies for malaria.
  - Validated
  - ()
  - 199
  - 126
  - 143
  - An effective vaccine against malaria is urgently required to relieve the immense human suffering and mortality caused by this parasite. A successful subunit vaccine against the liver stage of malaria will require the induction of high levels of protective T cells. Despite success in small animal models, DNA vaccines fail to induce strong cellular immune responses in humans. However, DNA vaccines can induce a T-cell response that can be strongly boosted by recombinant viral vectors. We have evaluated this heterologous prime-boost approach using the Plasmodium berghei mouse model for immunogenicity and protective efficacy against malaria challenge using combinations of plasmid DNA, recombinant modified vaccinia virus Ankara, fowlpox virus, and non-replicating adenovirus. We have proceeded to test immunogenicity and efficacy of successful heterologous prime-boost vaccines in phase I/IIa trials in malaria na�ve subjects in the UK and in semi-immune individuals in The Gambia. In these clinical trials, remarkably high levels of effector T-cell responses have been induced and significant protection documented in a human sporozoite challenge model. We summarize the preclinical design and development of these heterologous prime-boost vaccines and discuss the encouraging results that have been observed in vaccinated humans.
  - http://www3.interscience.wiley.com/journal/118767495/abstract
  - 10.1111/j.0105-2896.2004.00138.x
DA  - 2004/06
ER  - 

@article{V16246071,
   = {Moore AC,  Hill AV },
   = {2004},
   = {June},
   = {Immunological Reviews},
   = {Progress in DNA-based heterologous prime-boost immunization strategies for malaria.},
   = {Validated},
   = {()},
   = {199},
  pages = {126--143},
   = {{An effective vaccine against malaria is urgently required to relieve the immense human suffering and mortality caused by this parasite. A successful subunit vaccine against the liver stage of malaria will require the induction of high levels of protective T cells. Despite success in small animal models, DNA vaccines fail to induce strong cellular immune responses in humans. However, DNA vaccines can induce a T-cell response that can be strongly boosted by recombinant viral vectors. We have evaluated this heterologous prime-boost approach using the Plasmodium berghei mouse model for immunogenicity and protective efficacy against malaria challenge using combinations of plasmid DNA, recombinant modified vaccinia virus Ankara, fowlpox virus, and non-replicating adenovirus. We have proceeded to test immunogenicity and efficacy of successful heterologous prime-boost vaccines in phase I/IIa trials in malaria na�ve subjects in the UK and in semi-immune individuals in The Gambia. In these clinical trials, remarkably high levels of effector T-cell responses have been induced and significant protection documented in a human sporozoite challenge model. We summarize the preclinical design and development of these heterologous prime-boost vaccines and discuss the encouraging results that have been observed in vaccinated humans.}},
   = {http://www3.interscience.wiley.com/journal/118767495/abstract},
   = {10.1111/j.0105-2896.2004.00138.x},
  source = {IRIS}
}